急性B型肝炎的治療探討

鄭 仰志(Yang-Chih Cheng), 方 聖惟(Sheng-Uei Fang), 張 甄(Cheng Tiong), 謝 清睿(Ching-Ruey Hsieh), 羅 鴻源(Horng-Yuan Lou), 劉 正典(Jean-Dean Liu), 潘 憲(Shiann Pan), 張 君照(Chun-Chao Chang)

Research output: Contribution to journalArticlepeer-review

Abstract

Acute hepatitis B was decreasing after the policy of global hepatitis B virus (HBV) vaccination in Taiwan. However, sporadic cases of acute hepatitis B were still encountered in our daily practice. Non-vaccination, non-response or poor response to current hepatitis B vaccine may be the cause. In addition, immune-selected or antiviral selected mutant strain may also cause new HBV infection in post-vaccination era. Studies for acute hepatitis B are not as much as for chronic hepatitis B. What is the role of antiviral agent in treating acute hepatitis B? Articles involved antiviral treatments for acute hepatitis B were reviewed. These studies showed antiviral agent may be beneficial in severe acute hepatitis B. But antiviral agent may play no role for non-severe form because it may interfere normal immune reaction and also impair anti-HBs formation.
Original languageUndefined/Unknown
Pages (from-to)99-105
Number of pages7
JournalJournal of Internal Medicine of Taiwan
Volume22
Issue number2
DOIs
Publication statusPublished - Apr 1 2011

Keywords

  • 急性B型肝炎
  • 抗病毒治療
  • 干安能
  • Acute hepatitis B
  • Antiviral treatment
  • Lamivudine

Cite this